DEA Finalizes Measures to Expand Medication-Assisted Treatment
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Domestic Divisions
      • Foreign Divisions
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Forensic Sciences
      • GUARDS
      • Forensic Sciences Policy
      • Forensic Science Organizations
      • Forensic Science Contact
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
    • Education and Prevention
      • Family Summit
      • Red Ribbon
      • Kiki and the History of Red Ribbon Week
      • Red Ribbon Toolkit - Resources For Your Community
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Senior Citizens
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
      • Operation Warfighter
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • DEA Finalizes Measures to Expand Medication-Assisted Treatment

DEA Finalizes Measures to Expand Medication-Assisted Treatment

June 28, 2021
|
Share Article
|
Download Press Release
For Immediate Release
Contact: DEA Public Affairs
Phone Number: (202) 307-7977

Improved access will benefit rural and underserved areas with limited treatment options

WASHINGTON – The Drug Enforcement Administration today announced an important step to improve access to medications for opioid use disorder, especially in rural areas where those suffering with opioid use disorder may have limited treatment options.

Under the final rule published today, DEA registrants who are authorized to dispense methadone for opioid use disorder would be authorized to add a “mobile component” to their existing registration – eliminating the separate registration requirement for these mobile narcotic treatment programs (NTPs).  This will streamline the registration process and make it easier for registrants to provide needed services in remote or underserved areas.  The rule also outlines the reports and records that shall be maintained for NTPs that wish to expand the reach of their treatment programs by use of mobile components.

“In the United States, we have been facing an opioid epidemic for more than a decade,” said DEA Assistant Administrator for Diversion Control Tim McDermott.  “We are losing tens of thousands of Americans per year to opioid-involved overdoses.  The Administration, DOJ, DEA, HHS, among many others, are squarely focused on efforts to improve the use of medication-assisted treatment in order to reduce overdose deaths and help those with opioid-addictions recover.  Today’s action sends a very important message that we support the use of medication-assisted treatment for opioid use disorder and are using all the tools at our disposal to make treatment options available to anyone in need of them, anywhere in the country.”

“Today’s action by the DEA will improve access to life-saving medication for opioid use disorder, especially for those in underserved communities who face barriers to treatment.” said Acting Director of National Drug Control Policy Regina LaBelle. “This new rule is a significant step forward that supports the Biden-Harris Administration’s drug policy priorities, including expanding access to evidence-based treatment and advancing racial equity in our approach to drug policy.”

According to the Centers for Disease Control, provisional data indicate that there were more than 67,500 reported overdose deaths attributed to opioids during the 12-month period ending in November 2020.  This accounts for approximately three quarters of all drug overdose deaths in the United States. 

The demand for evidence-based medication-assisted treatment for substance use disorders, including opioid use disorder, has increased over the years, especially for services provided by NTPs.  In certain areas of the country – particularly rural, urban, and Tribal communities – this has resulted in long waiting lists and high services fees.  In addition, the distance to the nearest NTP or the lack of consistent access to transportation in rural and underserved communities may prevent or substantially impede access to these critical services. 

Methadone is one of three FDA-approved medications for opioid use disorder.  There are more than 1,900 narcotic treatment program locations across the country, including opioid treatment programs, withdrawal management services that utilize methadone, and compounders.

This final rule builds on existing experience and provides additional flexibility for NTPs in operating mobile components, subject to the regulatory restrictions put into place to prevent the diversion of controlled substances.

For more information, the final rule is available on the Federal Register.

# # #

Download Press Release
###
Opioids
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

@DEAHQ
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster